149 related articles for article (PubMed ID: 17716725)
1. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments.
Béduneau A; Saulnier P; Hindré F; Clavreul A; Leroux JC; Benoit JP
Biomaterials; 2007 Nov; 28(33):4978-90. PubMed ID: 17716725
[TBL] [Abstract][Full Text] [Related]
2. Brain targeting using novel lipid nanovectors.
Béduneau A; Hindré F; Clavreul A; Leroux JC; Saulnier P; Benoit JP
J Control Release; 2008 Feb; 126(1):44-9. PubMed ID: 18055056
[TBL] [Abstract][Full Text] [Related]
3. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133.
Bourseau-Guilmain E; Béjaud J; Griveau A; Lautram N; Hindré F; Weyland M; Benoit JP; Garcion E
Int J Pharm; 2012 Feb; 423(1):93-101. PubMed ID: 21683129
[TBL] [Abstract][Full Text] [Related]
5. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26.
Pang Z; Lu W; Gao H; Hu K; Chen J; Zhang C; Gao X; Jiang X; Zhu C
J Control Release; 2008 Jun; 128(2):120-7. PubMed ID: 18436327
[TBL] [Abstract][Full Text] [Related]
6. Production of a PEGylated Fab' of the anti-LINGO-1 Li33 antibody and assessment of its biochemical and functional properties in vitro and in a rat model of remyelination.
Pepinsky RB; Walus L; Shao Z; Ji B; Gu S; Sun Y; Wen D; Lee X; Wang Q; Garber E; Mi S
Bioconjug Chem; 2011 Feb; 22(2):200-10. PubMed ID: 21254764
[TBL] [Abstract][Full Text] [Related]
7. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes.
Schnyder A; Krähenbühl S; Török M; Drewe J; Huwyler J
Biochem J; 2004 Jan; 377(Pt 1):61-7. PubMed ID: 14516278
[TBL] [Abstract][Full Text] [Related]
8. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.
Leong SR; DeForge L; Presta L; Gonzalez T; Fan A; Reichert M; Chuntharapai A; Kim KJ; Tumas DB; Lee WP; Gribling P; Snedecor B; Chen H; Hsei V; Schoenhoff M; Hale V; Deveney J; Koumenis I; Shahrokh Z; McKay P; Galan W; Wagner B; Narindray D; Hébert C; Zapata G
Cytokine; 2001 Nov; 16(3):106-19. PubMed ID: 11741351
[TBL] [Abstract][Full Text] [Related]
9. Study of the transcytosis of an anti-transferrin receptor antibody with a Fab' cargo across the blood-brain barrier in mice.
Manich G; Cabezón I; del Valle J; Duran-Vilaregut J; Camins A; Pallàs M; Pelegrí C; Vilaplana J
Eur J Pharm Sci; 2013 Jul; 49(4):556-64. PubMed ID: 23748097
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeling and targeting of lipidic nanocapsules for applications in radioimmunotherapy.
Jestin E; Mougin-Degraef M; Faivre-Chauvet A; Remaud-Le Saëc P; Hindre F; Benoit JP; Chatal JF; Barbet J; Gestin JF
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):51-60. PubMed ID: 17372573
[TBL] [Abstract][Full Text] [Related]
11. Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.
Humphreys DP; Heywood SP; Henry A; Ait-Lhadj L; Antoniw P; Palframan R; Greenslade KJ; Carrington B; Reeks DG; Bowering LC; West S; Brand HA
Protein Eng Des Sel; 2007 May; 20(5):227-34. PubMed ID: 17452434
[TBL] [Abstract][Full Text] [Related]
12. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells.
Deng L; Zhang Y; Ma L; Jing X; Ke X; Lian J; Zhao Q; Yan B; Zhang J; Yao J; Chen J
Int J Nanomedicine; 2013; 8():3271-83. PubMed ID: 24023515
[TBL] [Abstract][Full Text] [Related]
13. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26.
Aktaş Y; Yemisci M; Andrieux K; Gürsoy RN; Alonso MJ; Fernandez-Megia E; Novoa-Carballal R; Quiñoá E; Riguera R; Sargon MF; Celik HH; Demir AS; Hincal AA; Dalkara T; Capan Y; Couvreur P
Bioconjug Chem; 2005; 16(6):1503-11. PubMed ID: 16287248
[TBL] [Abstract][Full Text] [Related]
14. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.
Messerschmidt SK; Musyanovych A; Altvater M; Scheurich P; Pfizenmaier K; Landfester K; Kontermann RE
J Control Release; 2009 Jul; 137(1):69-77. PubMed ID: 19306900
[TBL] [Abstract][Full Text] [Related]
15. Monocyte/macrophage interactions with base and linear- and star-like PEG-modified PEG-poly(acrylic acid) co-polymers.
Wagner VE; Bryers JD
J Biomed Mater Res A; 2003 Jul; 66(1):62-78. PubMed ID: 12833432
[TBL] [Abstract][Full Text] [Related]
16. Entrance effects at nanopores of nanocapsules functionalized with poly(ethylene glycol) and their flow through nanochannels.
Popa R; Vrânceanu M; Nikolaus S; Nirschl H; Leneweit G
Langmuir; 2008 Nov; 24(22):13030-6. PubMed ID: 18950201
[TBL] [Abstract][Full Text] [Related]
17. Effect of polyethylene glycol conjugation on conformational and colloidal stability of a monoclonal antibody antigen-binding fragment (Fab').
Roque C; Sheung A; Rahman N; Ausar SF
Mol Pharm; 2015 Feb; 12(2):562-75. PubMed ID: 25548945
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
19. Chemical production of bispecific antibodies.
Graziano RF; Guptill P
Methods Mol Biol; 2004; 283():71-85. PubMed ID: 15197303
[TBL] [Abstract][Full Text] [Related]
20. High-yield coupling of antibody Fab' fragments to liposomes containing maleimide-functionalized lipids.
Shahinian S; Silvius JR
Methods Enzymol; 2004; 387():3-15. PubMed ID: 15172154
[No Abstract] [Full Text] [Related]
[Next] [New Search]
